Get the Stockscreener App
6.89
0.43%
-0.03
Fibrogen Inc stock is traded at $6.89, with a volume of 14,398.
It is down -0.43% in the last 24 hours and up +30.74% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$6.92
Open:
$6.85
24h Volume:
14,398
Relative Volume:
0.35
Market Cap:
$27.85M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-2.3515
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
-7.52%
1M Performance:
+30.74%
6M Performance:
-43.02%
1Y Performance:
-41.36%
1-Day Range:
$6.805
$7.03
1-Week Range:
$6.8001
$7.51
52-Week Range:
$4.50
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
6.89 | 27.97M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
What is the dividend policy of FibroGen Inc. stockExpert Picks Signals To Watch Now - jammulinksnews.com
What are analysts’ price targets for FibroGen Inc. in the next 12 monthsPre Market Review For Consistent Profits - jammulinksnews.com
FibroGen Inc. Recovery Potential Based on Technical ToolsTechnical Entry Strategy for Beginners Explained - metal.it
Sector Leaders Rotate Capital Into FibroGen Inc.Trade Timing Strategy With Technical Data Explained - metal.it
FibroGen Inc. Hits Oversold Level on RSI IndicatorConsistent Profit Pattern Recognition Tools Shared - metal.it
Published on: 2025-07-29 03:32:03 - metal.it
What are FibroGen Inc. company’s key revenue driversUnprecedented profits - jammulinksnews.com
Should I hold or sell FibroGen Inc. stock in 2025Invest confidently with professional market insights - jammulinksnews.com
Is FibroGen Inc. a growth stock or a value stockUnmatched market performance - jammulinksnews.com
What are the technical indicators suggesting about FibroGen Inc.Consistent wealth multiplication - jammulinksnews.com
How strong is FibroGen Inc. company’s balance sheetRobust investment performance - jammulinksnews.com
Is it the right time to buy FibroGen Inc. stockExplosive returns - jammulinksnews.com
What is the risk reward ratio of investing in FibroGen Inc. stockExceptional market performance - jammulinksnews.com
How volatile is FibroGen Inc. stock compared to the marketBreakthrough investment results - jammulinksnews.com
What makes FibroGen Inc. stock price move sharplyCarefully Curated High Return Stocks - metal.it
Why FibroGen Inc. stock attracts strong analyst attentionFree VIP Investment Strategies - metal.it
FibroGen Inc. Stock Analysis and ForecastConsistently superior profits - PrintWeekIndia
Will FibroGen Inc. stock split in the near futureSuperior portfolio returns - jammulinksnews.com
What drives FibroGen Inc. stock priceExplosive returns - PrintWeekIndia
Is FibroGen Inc. stock a good hedge against inflationPhenomenal wealth increase - jammulinksnews.com
Is FibroGen Inc. a good long term investmentExplosive capital gains - PrintWeekIndia
What risks could impact FibroGen Inc. stock performanceTremendous return on equity - jammulinksnews.com
What analysts say about FibroGen Inc. stockExceptional return forecasts - PrintWeekIndia
40-Year Biotech Veteran Jim Schoeneck Joins Connect Biopharma Board as Asthma Drug Enters Critical Phase - Stock Titan
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrogen Inc Stock (FGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):